Oxford BioDynamics: Seeking deals to enhance EpiSwitch revenue potential
There is a near-term focus on partnerships, collaborations and licensing deals to maximise the revenue potential of Oxford BioDynamics’ portfolio of innovative and clinically robust tests. We believe the market opportunities for CiRT, PSE, and the portfolio of tests remain intact and sizeable, but successful uptake requires continued significant commercial investment and/or partners, in our view. New management is considering all options to crystallise value from these diagnostic tests and the in-depth knowledge of 3-dimensional genomics that underpin the proprietary EpiSwitch platform. Our reinstated DCF-based valuation is now £159m ($199m), or 8p/share, which assumes OBD can deliver on the revenue and value potential that exists.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.